



[Home](#) / [Investors](#) / [Press Releases](#)

Insmmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

-- *Insmmed Leads Science Top Employers List for Third Consecutive Year* --

BRIDGEWATER, N.J., Oct. 26, 2023 /PRNewswire/ -- Insmmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has earned the highest ranking in *Science's* 2023 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

"I am immensely proud to have been ranked the No. 1 employer in *Science's* annual survey for the third year in a row—something that only Genentech and Regeneron have achieved in the list's more than 20-year history," said Will Lewis, Chair and Chief Executive Officer of Insmmed. "At Insmmed, we know that our people are our most valuable asset, and it is because of them that we have received this honor once again. I would like to thank our colleagues around the world for their commitment to one another, the pursuit of groundbreaking science, the patients we serve, and the communities around us."

The 2023 survey results were based on more than 6,800 responses from individuals across North America (59%), Europe (18%), Asia/Pacific Rim (16%), and other locations (7%). This year's highest-ranking companies stood out in the areas of innovative leadership, respect for employees, social responsibility, values alignment, and employee loyalty. Following Insmmed, the top five companies in 2023 included Incyte, Alnylam, Regeneron, and Syngenta Group.

"Receiving the title of Top Biopharma Employer once again is an incredible honor and a testament to the unique and special culture that we have built," said Nicole Schaeffer, Chief People Strategy Officer of Insmmed. "Our organization has always put our people, the science, and the patients we serve at the forefront. As we approach an exciting year and prepare for continued growth ahead, it is inspiring to witness our employees' commitment to not only upholding our culture, but also continuing to strengthen and enrich it as our company evolves."

The complete feature and company rankings can be accessed [here](#). To learn more about Insmmed's culture and explore opportunities to join our team, please visit <https://insmed.com/culture/careers/>.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmmed
(646) 812-4030
bryan.dunn@insmed.com

Eleanor Barisser
Associate Director, Investor Relations
Insmmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmmed
(732) 718-3621
amanda.fahey@insmed.com

SOURCE Insmmed Incorporated
